JP7393337B2 - 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 - Google Patents

抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 Download PDF

Info

Publication number
JP7393337B2
JP7393337B2 JP2020542138A JP2020542138A JP7393337B2 JP 7393337 B2 JP7393337 B2 JP 7393337B2 JP 2020542138 A JP2020542138 A JP 2020542138A JP 2020542138 A JP2020542138 A JP 2020542138A JP 7393337 B2 JP7393337 B2 JP 7393337B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513331A (ja
Inventor
如迪 ▲包▼
▲海▼清 花
素霞 ▲劉▼
福▲軍▼ ▲張▼
▲ティン▼ 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of JP2021513331A publication Critical patent/JP2021513331A/ja
Priority to JP2023197481A priority Critical patent/JP2024026132A/ja
Application granted granted Critical
Publication of JP7393337B2 publication Critical patent/JP7393337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2020542138A 2018-02-11 2019-02-01 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 Active JP7393337B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023197481A JP2024026132A (ja) 2018-02-11 2023-11-21 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810142118 2018-02-11
CN201810142118.6 2018-02-11
PCT/CN2019/074397 WO2019154315A1 (zh) 2018-02-11 2019-02-01 抗b7-h4抗体、其抗原结合片段及其医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023197481A Division JP2024026132A (ja) 2018-02-11 2023-11-21 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途

Publications (2)

Publication Number Publication Date
JP2021513331A JP2021513331A (ja) 2021-05-27
JP7393337B2 true JP7393337B2 (ja) 2023-12-06

Family

ID=67548182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542138A Active JP7393337B2 (ja) 2018-02-11 2019-02-01 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP2023197481A Pending JP2024026132A (ja) 2018-02-11 2023-11-21 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023197481A Pending JP2024026132A (ja) 2018-02-11 2023-11-21 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途

Country Status (11)

Country Link
US (1) US11472882B2 (https=)
EP (1) EP3753951A4 (https=)
JP (2) JP7393337B2 (https=)
CN (2) CN116693686A (https=)
AU (1) AU2019218319B2 (https=)
BR (1) BR112020015736A2 (https=)
CA (1) CA3089246A1 (https=)
MX (1) MX2020008181A (https=)
TW (1) TWI823895B (https=)
WO (1) WO2019154315A1 (https=)
ZA (1) ZA202004701B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024026132A (ja) * 2018-02-11 2024-02-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014960A (es) * 2019-06-06 2022-03-04 Shanghai Hansoh Biomedical Co Ltd Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
CN115298220B (zh) * 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
CA3183994A1 (en) 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
IL310780A (en) * 2020-08-18 2024-04-01 Abl Bio Inc Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof
JP2024501894A (ja) 2021-01-04 2024-01-16 メルサナ セラピューティクス インコーポレイテッド Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
US20240309095A1 (en) * 2021-07-07 2024-09-19 Incyte Corporation Anti-b7-h4 antibodies and uses thereof
AR127806A1 (es) * 2021-12-01 2024-02-28 Kadmon Corp Llc Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15
JP2025500457A (ja) * 2021-12-23 2025-01-09 プロシーナ バイオサイエンシーズ リミテッド ソルチリンを認識する抗体
CA3245849A1 (en) * 2022-03-30 2025-02-03 Duality Biologics (Suzhou) Co., Ltd. ANTIBODY-DRUG CONJUGATE B7H4 AND ITS USE
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2024213081A1 (zh) 2023-04-12 2024-10-17 上海翰森生物医药科技有限公司 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505372A (ja) 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクウィブ カンパニー 抗ｂ７ｈ４モノクローナル抗体−薬物コンジュゲートおよび使用方法
WO2016160620A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091580A1 (en) * 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
US6858710B2 (en) * 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
EP3058955B1 (en) * 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US8759490B2 (en) * 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
JP6120848B2 (ja) * 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
AU2014244424A1 (en) * 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN103981150B (zh) * 2014-03-28 2016-06-01 苏州大学 抗人b7-h4单克隆抗体及其制备和应用
JP6943760B2 (ja) * 2014-09-12 2021-10-06 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及び免疫複合体
WO2018021301A1 (ja) * 2016-07-26 2018-02-01 静岡県 抗ｂ７－ｈ４抗体
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
EP3753951A4 (en) * 2018-02-11 2022-03-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
MA52416A (fr) * 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505372A (ja) 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクウィブ カンパニー 抗ｂ７ｈ４モノクローナル抗体−薬物コンジュゲートおよび使用方法
WO2016160620A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024026132A (ja) * 2018-02-11 2024-02-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途

Also Published As

Publication number Publication date
BR112020015736A2 (pt) 2020-12-08
AU2019218319B2 (en) 2025-11-13
JP2024026132A (ja) 2024-02-28
US11472882B2 (en) 2022-10-18
US20210032347A1 (en) 2021-02-04
TWI823895B (zh) 2023-12-01
ZA202004701B (en) 2023-12-20
AU2019218319A1 (en) 2020-08-13
CN116693686A (zh) 2023-09-05
TW201934581A (zh) 2019-09-01
KR20200119846A (ko) 2020-10-20
EP3753951A1 (en) 2020-12-23
CN110366560B (zh) 2023-07-28
CA3089246A1 (en) 2019-08-15
JP2021513331A (ja) 2021-05-27
MX2020008181A (es) 2020-09-18
CN110366560A (zh) 2019-10-22
WO2019154315A1 (zh) 2019-08-15
EP3753951A4 (en) 2022-03-16
RU2020124155A (ru) 2022-03-11

Similar Documents

Publication Publication Date Title
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
JP2023075294A (ja) 抗ｃｄ４７抗体及びその応用
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
TW202132351A (zh) 抗cd47/抗pd-l1抗體及其應用
JP2021510533A (ja) 抗４−１ｂｂ抗体、その抗原結合フラグメント、およびその医学的使用
JP7538131B2 (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
TW202317631A (zh) 抗crtam抗體及其應用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN115335402B (zh) 特异性抗原结合分子,其制备方法及医药用途
CN121079322A (zh) 抗cd27单克隆抗体及其应用
RU2792748C2 (ru) Антитело к b7-h4, его антигенсвязывающий фрагмент и его фармацевтическое применение
KR102952441B1 (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
JP2026501455A (ja) Ｃｄ１１２ｒを標的する抗体またはその抗原結合断片およびそれらの使用
KR20260053095A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231124

R150 Certificate of patent or registration of utility model

Ref document number: 7393337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02